5,136 results on '"PRAMIPEXOLE"'
Search Results
2. A Study to Assess the Effects of Dexpramipexole in Participants with Eosinophilic COPD (SUSPIRE-1)
3. Precision Care for Major Depressive Disorder
4. Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD) (OCD-RT)
5. Phase III Long-Term Extension Study With Dexpramipexole (EXHALE-5)
6. A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4)
7. A Study in Healthy People to Compare Two Different Sifrol® Tablets
8. Pramipexole to Enhance Social Connections
9. Pramipexole for Anhedonic Depression (PRIME-PRAXOL)
10. Long-term Efficacy of Pramipexole in Anhedonic Depression (LONG-PRAXOL)
11. Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)
12. Gait Analysis in Neurological Disease
13. Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
14. Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD
15. A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) (EXHALE-3)
16. A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2)
17. The Interplay of Mitochondrial Bioenergetics and Dopamine Agonists as an Effective Disease-Modifying Therapy for Parkinson's Disease.
18. Pramipexole Hyperactivates the External Globus Pallidus and Impairs Decision-Making in a Mouse Model of Parkinson's Disease.
19. Alterations in functional brain connectivity following treatment for restless legs syndrome: The role of symptom improvement in restoring functional connectivity.
20. Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6‐OHDA‐induced degeneration.
21. Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
22. Profile of Depressive Symptoms in Parkinsons Disease
23. Three paradoxes related to the mode of action of pramipexole: The path from D2/D3 dopamine receptor stimulation to modification of dopamine-modulated functions.
24. Pramipexole improves depression-like behavior in diabetes mellitus with depression rats by inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing impaired neuroplasticity.
25. Dopamine agonists in restless leg syndrome treatment and their effects on sleep parameters: A systematic review and meta-analysis.
26. The effects of pramipexole on motivational vigour during a saccade task: a placebo-controlled study in healthy adults.
27. Current evidence and future perspectives in the exploration of sleep-related eating disorder--a systematic literature review.
28. Targets to Search for New Pharmacological Treatment in Idiopathic Parkinson's Disease According to the Single-Neuron Degeneration Model.
29. Social Decision Making in Parkinson's Disease
30. Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression (APQ-TRD)
31. Pramipexole for the Treatment of Depression: Efficacy and Mechanisms
32. Dopamine agonists in the treatment of Parkinson's disease: the show must go on
33. Novel SLC18A2 Variant in Infantile Dystonia-Parkinsonism Type 2.
34. Impulse control disorders in Parkinson's disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis.
35. Comparison of the effectiveness, safety, and costs of anti‐Parkinson drugs: A multiple‐center retrospective study.
36. In vitro drug screening models derived from different PC12 cell lines for exploring Parkinson's disease based on electrochemical signals of catecholamine neurotransmitters.
37. Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson's Disease.
38. Structure Identification and Risk Assurance of Unknown Impurities in Pramipexole Oral Drug Formulation.
39. A Randomized Phase 3 Study Comparing P2B001 to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's Disease.
40. Optimization of Pramipexole-Loaded In Situ Thermosensitive Intranasal Gel for Parkinson's Disease.
41. Pramipexole Enhances Reward Learning by Preserving Value Estimates.
42. Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma (EXHALE-1)
43. Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets (PLKS-BE)
44. A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
45. Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
46. Pramipexole and Morphine for Renal Colic
47. Pramipexole-induced syndrome of inappropriate antidiuretic hormone secretion in a patient with young-onset Parkinson’s disease
48. Long-term repetitive transcranial magnetic stimulation for treatment-resistant depression: Report of two cases.
49. Restless limbs and bladder: an atypical variant of restless legs syndrome case report.
50. Striatal mechanism of the restless legs syndrome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.